ArticleThe American journal of psychiatry2024
Neuromelanin-Sensitive MRI as Candidate Marker for Treatment Resistance in First-Episode Schizophrenia.
Article in The American journal of psychiatry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 32 citations in OpenAlex.
- A frontotemporal dementia-like phenotype in schizophrenia: links to striatal dopamine and iron accumulation.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Observational
- The mechanism underlying tardive dyskinesia: an exploratory test of the dopamine overactivity hypothesis using MRI imaging of midbrain neuromelanin.Psychopharmacology · 2026Article
- Schizophrenia: from mechanism to therapy.Science China. Life sciences · 2026Review
- Postpartum psychosis is associated with elevated neuromelanin-MRI signal in the midbrain.Molecular psychiatry · 2026Article
- Clinical deep phenotyping of treatment response in schizophrenia (CDP-STAR): design and methodology of a prospective multimodal observational study.European archives of psychiatry and clinical neuroscience · 2026Observational
- Bioenergetic and early treatment response stratification (BIOERES): a two-variable prognostic model for early identification of treatment-resistance schizophrenia.Translational psychiatry · 2026Article
- Associations of neuromelanin in the substantia nigra with antipsychotic response in schizophrenia.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Article
- The potential of neuromelanin-sensitive MRI in psychiatric disorders.Neuroscience applied · 2026Review
- Functional, Structural, and AI-Based MRI Analysis: A Comprehensive Review of Recent Advances.Diagnostics (Basel, Switzerland) · 2025Review
- Restoring Course as a Core Diagnostic Element of Psychotic Disorders.Schizophrenia bulletin · 2025Review
- Reduced Brain Iron and Striatal Hyperdopaminergia in Schizophrenia: A Quantitative Susceptibility Mapping MRI and PET Study.The American journal of psychiatry · 2025Article
- An ace in the hole? Opportunities and limits of using mice to understand schizophrenia neurobiology.Molecular psychiatry · 2025Review
- Translational Evidence for Dopaminergic Rewiring of the Basal Ganglia in Persons with Schizophrenia.medRxiv : the preprint server for health sciences · 2025Article
- The hypothesis of biologically based subtypes of schizophrenia: a 10-year update.World psychiatry : official journal of the World Psychiatric Association (WPA) · 2025Article
- Longitudinal neuromelanin changes in prodromal and early Parkinson's disease in humans and rat model.Brain communications · 2025Article
- Magnetic resonance imaging of postmortem human brain specimens: methodological considerations and prospects in psychoradiology.Psychoradiology · 2025Article
- Response to clozapine in treatment resistant schizophrenia is related to alterations in regional cerebral blood flow.Schizophrenia (Heidelberg, Germany) · 2024Article
- Neuromelanin-sensitive MRI for mechanistic research and biomarker development in psychiatry.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024Review
- Fronto-striato-thalamic circuit connectivity and neuromelanin in schizophrenia: an fMRI and neuromelanin-MRI study.Schizophrenia (Heidelberg, Germany) · 2023Article
- Striatal dopamine synthesis capacity and neuromelanin in the substantia nigra: A multimodal imaging study in schizophrenia and healthy controls.Neuroscience applied · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
objectiveMarkers for treatment resistance in schizophrenia are needed to reduce delays in effective treatment. Nigrostriatal hyperdopaminergic function plays a critical role in the pathology of schizophrenia, yet antipsychotic nonresponders do not show increased dopamine function. Neuromelanin-sensitive MRI (NM-MRI), which indirectly measures dopamine function in the substantia nigra, has potential as a noninvasive marker for nonresponders. Increased NM-MRI signal has been shown in psychosis, but has not yet been assessed in nonresponders. In this study, the authors investigated whether nonresponders show lower NM-MRI signal than responders.
methodsNM-MRI scans were acquired in 79 patients with first-episode psychosis and 20 matched healthy control subjects. Treatment response was assessed at a 6-month follow-up. An a priori voxel-wise analysis within the substantia nigra tested the relation between NM-MRI signal and treatment response in patients.
resultsFifteen patients were classified as nonresponders and 47 patients as responders. Seventeen patients were excluded, primarily because of medication nonadherence or change in diagnosis. Voxel-wise analysis revealed 297 significant voxels in the ventral tier of the substantia nigra that were negatively associated with treatment response. Nonresponders and healthy control subjects had significantly lower NM-MRI signal than responders. Receiver operating characteristic curve analysis showed that NM-MRI signal separated nonresponders with areas under the curve between 0.62 and 0.85. In addition, NM-MRI signal in patients did not change over 6 months.
conclusionsThese findings provide further evidence for dopaminergic differences between medication responders and nonresponders and support the potential of NM-MRI as a clinically applicable marker for treatment resistance in schizophrenia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.